Orserdu (Elacestrant)

Elacestrant, the active ingredient in Orserdu, is a selective estrogen receptor degrader presented as an oral tablet for oral use. It is indicated for the treatment of advanced estrogen receptor‑positive, HER2‑negative breast cancer in post‑menopausal patients who have progressed on prior endocrine therapy.

GNH USA supplies Orserdu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Elacestrant is a selective estrogen receptor degrader used in the management of hormone‑responsive breast cancer.

Advanced ER+/HER2‑negative breast cancer: provides an oral SERD option after progression on prior endocrine therapy. Metastatic hormone‑receptor‑positive breast cancer: helps delay disease progression and may improve progression‑free survival. Post‑menopausal ER‑positive breast cancer: offers a non‑injectable treatment alternative.

Elacestrant may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or lack of energy. - Hot flashes: transient sensation of warmth. - Diarrhea: loose stools, usually self‑limiting. - Headache: mild cranial discomfort.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Interstitial lung disease: cough, dyspnea, and radiographic infiltrates. - Severe liver injury: elevated transaminases, jaundice. - QT interval prolongation: risk of cardiac arrhythmia.

Before initiating elacestrant therapy, several safety considerations should be reviewed. - Pregnancy: avoid use due to potential teratogenic effects. - Breastfeeding: not recommended as drug may be excreted in milk. - Liver impairment: assess function; dose adjustment may be required. - Concomitant QT‑prolonging drugs: monitor ECG for arrhythmia risk. - Drug interactions: evaluate CYP3A4 inhibitors or inducers. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Elacestrant interacts with several medicines that affect its metabolism or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase elacestrant exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmia. - Other SERDs or selective estrogen modulators: may cause additive hormonal effects. - Anticoagulants (e.g., warfarin): heightened risk of thrombotic events.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise plasma levels. - Hormonal therapies (e.g., aromatase inhibitors): monitor for overlapping toxicity. - Statins metabolized by CYP3A4 (e.g., simvastatin): observe for increased concentrations. - Antidepressants affecting QT (e.g., citalopram): watch ECG changes. - Herbal supplements (e.g., St. John’s wort): possible induction of metabolism.